|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Applying LOH analysis in 52 MCL patient samples, we confirmed frequent alterations in 9p21 (28.6%) and p53 (28.9%) but also detected allelic losses in 1p21, 9q21, 13q13-14, 13q31-32, 17p13.1, and 17p13.3 in 28-45% of cases and allelic gains in 3q27-28 and 19p13.3 in 14-22% of cases.
|
19137297 |
2009 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, GeneChip analyses identified different genes, encoding proteins involved in microtubule dynamics, such as MAP2, MAP6 and TP53, as targets for chromosomal aberration in MCL.
|
19016712 |
2009 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings support the use of bendamustine as a therapeutic agent, alone or in combination, for CLL and MCL with p53 alterations and describe the molecular basis of its activity in these entities.
|
18980985 |
2008 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment of wild-type p53 mantle cell lymphoma (MCL) cell lines with MI-63 resulted in a dose- and time-dependent inhibition of proliferation, with an IC(50) in the 0.5 to 5.0 micromol/L range.
|
18765533 |
2008 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This information on molecular phenotypes may provide new areas of investigation for ATM function or may be exploited by designing specific therapies for MCL cases with p53 aberrations.
|
16461462 |
2006 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
|
16166592 |
2006 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cryptic and complex chromosomal rearrangements and the deletion of TP53 gene in a patient with leukemic mantle cell lymphoma.
|
16938577 |
2006 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study highlights the genomic profile as a predictor for clinical outcome and suggests that "genome scanning" of chromosomes 1p21, 9q21-q22, 9p21.3-P16/INK4a, and 17p13.1-TP53 may be clinically useful in MCL.
|
15718413 |
2005 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, p53 is frequently targeted by alterations in MCL.
|
16155021 |
2005 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Loss of 17p and gain of 3q, known to be associated with disease progression in MCL, were detected with M-FISH and confirmed with the use of p53 and BCL6 probes together with comparative genomic hybridization, which detected also an interstitial deletion on 7p21.
|
15381376 |
2004 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to assess the frequency, relationship and impact of p53 abnormalities and those of its inhibitor mdm2 in blastoid and non-blastoid MCL in leukemic phase.
|
12414343 |
2002 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chromosome 17 abnormalities are common in leukemic MCL, may be involved in pathogenesis, and are associated with p53 expression.
|
11706075 |
2001 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Correlation of MCL p53 and p27 expression with clinical data showed an association between reduced overall survival rates and the overexpression of p53 (P =.001), the loss of p27 (P =.002), or both.
|
10627471 |
2000 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A high incidence of p53 gene alterations was found, almost equivalent in aCLL and MCL.
|
10980628 |
2000 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Proliferative fraction, bcl-1 gene translocation, and p53 mutation status as markers in mantle cell lymphoma.
|
10085408 |
1999 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Several reports have shown that p53 mutations in MCL lead to blastoid transformation and a worse prognosis; however, the role of p53 mutations in MM with t(11;14) is unclear.
|
10223569 |
1999 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
110 cases of MCL have been analysed for their cytomorphological features, mitotic and proliferation indices, bcl-1 rearrangements, p53 expression patterns and DNA content by both interphase cytogenetic as well as DNA flow cytometric analyses.
|
10037001 |
1998 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We previously found that cases of typical B-chronic lymphocytic leukemia (CLL), atypical B-CLL with t(11;14) and mantle cell lymphomas characterized by rapid progression of the disease and resistance to therapy, had mutations of the TP53 gene.
|
9844609 |
1998 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Blastoid MCL subtypes were characterized by distinctly elevated mitotic counts (57 and 51/10 HPF v 21/10 high-power fields in common MCL), proliferation indices (58% and 53% v 27% in common types, respectively; P < .001), frequent bcl-1 rearrangements at the major translocation cluster locus (59% v 40%), and overexpression of p53 (21% v 6%).
|
9028966 |
1997 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings indicate that in B-NHL, somatic changes in P53 were present in diagnostic specimens of all histologic types, but at a higher frequency in DLC and MC tumors.
|
9354678 |
1997 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
On the other hand, the molecular basis of some of these diseases (eg, the overexpression of the Prad1/CCND1 gene in mantle-cell lymphomas, the relationship between bcl-2 and bax expression in chronic lymphocytic leukemia homeostasis, the role of p53 tumor suppressor gene mutations in chronic lymphocytic leukemia progression) are increasingly well known.
|
9090492 |
1997 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The two cases with p53 mutations showed p21Waf1 and p16INK4a expression whereas the 4 aggressive MCLs with p16INK4a and p21Waf1 gene alterations had a wild-type p53. p21Waf1 and p16INK4a were expressed at mRNA and protein levels in all typical MCLs examined.
|
8978301 |
1997 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From these findings and from data available in the literature the conclusion can be drawn that p53 gene mutations at codons 158 and 167 may be associated with lymphoproliferative disorders and that low- or intermediate-grade NHL, including leukemic mantle cell lymphoma, may frequently carry this genetic change.
|
8603336 |
1996 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, no mutations were detected in exons 5-9 in this case. p53 expression was also detected in 10% of the cells in an additional large cell type of MCL and in less than 1% of the cells in 6 typical cases.
|
8605352 |
1996 |
|
Mantle cell lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of 21 cases with variant cytology (ie, anaplastic or blastic), 6 (28.6%) had p53 mutations as compared with only 2 of 32 cases (6.3%) with typical MCL cytology (P = .05), and p53 mutations preceded the development of variant cytology in 2 patients.
|
8639789 |
1996 |